Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Human Genome Epidemiology Literature Finder|Home|PHGKB

Human Genome Epidemiology Literature Finder


Last data update: Dec 5, 2023. (Total: 223688Documents)
   dataset        GWAS Only
Filtered By:

Previous    

Records 1 - 9 (of 9 Records)

Query Trace: Nausea and PIK3CA[original query]
A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma.
Clinical colorectal cancer 2016 Mar .
Bowles Daniel W, Kochenderfer Mark, Cohn Allen, Sideris Lucas, Nguyen Nghia, Cline-Burkhardt Vivian, Schnadig Ian, Choi Minsig, Nabell Lisle, Chaudhry Arvind, Ruxer Robert, Ucar Antonio, Hausman Diana, Walker Luke, Spira Alexander, Jimeno Anton
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Cancer discovery 2017 Mar .
Juric Dejan, Krop Ian, Ramanathan Ramesh K, Wilson Timothy R, Ware Joseph A, Sanabria Bohorquez Sandra, Savage Heidi, Sampath Deepak, Salphati Laurent, Lin Ray, Jin Huan, Parmar Hema, Hsu Jerry Y, Von Hoff Daniel D, Baselga Jo
Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer.
Cancer science 2018 Jun .
Osumi Hiroki, Shinozaki Eiji, Mashima Tetsuo, Wakatsuki Takeru, Suenaga Mitsukuni, Ichimura Takashi, Ogura Mariko, Ota Yumiko, Nakayama Izuma, Takahari Daisuke, Chin Keisho, Miki Yoshio, Yamaguchi Kens
Phosphatidylinositol 3-Kinase ?-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 2 36 (13): 1291-1299.
Juric Dejan, Rodon Jordi, Tabernero Josep, Janku Filip, Burris Howard A, Schellens Jan H M, Middleton Mark R, Berlin Jordan, Schuler Martin, Gil-Martin Marta, Rugo Hope S, Seggewiss-Bernhardt Ruth, Huang Alan, Bootle Douglas, Demanse David, Blumenstein Lars, Coughlin Christina, Quadt Cornelia, Baselga Jo
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.
International journal of cancer 2019 Nov .
Myers Andrea P, Konstantinopoulos Panagiotis A, Barry William T, Luo Weixiu, Broaddus Russell R, Makker Vicky, Drapkin Ronny, Liu Joyce, Doyle Austin, Horowitz Neil S, Meric-Bernstam Funda, Birrer Michael, Aghajanian Carol, Coleman Robert L, Mills Gordon B, Cantley Lewis C, Matulonis Ursula A, Westin Shannon
Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.
The oncologist 2020 12 26 (4): 290-e545.
van Brummelen Emilie M J, Huijberts Sanne, van Herpen Carla, Desar Ingrid, Opdam Frans, van Geel Robin, Marchetti Serena, Steeghs Neeltje, Monkhorst Kim, Thijssen Bas, Rosing Hilde, Huitema Alwin, Beijnen Jos, Bernards Rene, Schellens J
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2020 11 27 (7): 1842-1849.
Narayan Preeti, Prowell Tatiana M, Gao Jennifer J, Fernandes Laura L, Li Emily, Jiang Xiling, Qiu Junshan, Fan Jianghong, Song Pengfei, Yu Jingyu, Zhang Xinyuan, King-Kallimanis Bellinda L, Chen Wei, Ricks Tiffany K, Gong Yutao, Wang Xing, Windsor Katherine, Rhieu Steve Y, Geiser Gerlie, Banerjee Anamitro, Chen Xiaohong, Reyes Turcu Francisca, Chatterjee Deb K, Pathak Anand, Seidman Jeffrey, Ghosh Soma, Philip Reena, Goldberg Kirsten B, Kluetz Paul G, Tang Shenghui, Amiri-Kordestani Laleh, Theoret Marc R, Pazdur Richard, Beaver Julia
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86).
Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Jan .
Dhani Neesha C, Hirte Hal W, Wang Lisa, Burnier Julia V, Jain Angela, Butler Marcus O, Welch Stephen, Fleming Gini F, Hurteau Jean, Matsuo Koji, Matei Daniela, Jimenez Waldo, Johnston Carolyn, Cristea Mihaela, Tonkin Katia, Ghatage Prafull, Lheureux Stephanie, Mehta Anjali, Quintos Judy, Tan Qian, Kamel-Reid Suzanne, Ludkovski Olga, Tsao Ming-Sound, Wright John J, Oza Amit
Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.
JCO precision oncology 2022 2 6 e2100424.
Krop Ian E, Jegede Opeyemi A, Grilley-Olson Juneko E, Lauring Josh D, Mitchell Edith P, Zwiebel James A, Gray Robert J, Wang Victoria, McShane Lisa M, Rubinstein Larry V, Patton David, Williams P Mickey, Hamilton Stanley R, Kono Scott A, Ford James M, Garcia Agustin A, Sui Xingwei D, Siegel Robert D, Slomovitz Brian M, Conley Barbara A, Arteaga Carlos L, Harris Lyndsay N, O'Dwyer Peter J, Chen Alice P, Flaherty Keith
TOP